Payment overview · 2025
General Payments
$83.61
4 reported records · 2 companies
Healthcare provider profile · identity verified
Deborah M Greer, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SUMTERVILLE, FL · NPI 1780607846
Verified facts
What the public records show
CMS Open Payments records show Deborah M Greer, ARNP received $83.61 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 53.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.46 | 53.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.15 | 46.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $83.61 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.46 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 151 |
| Amlodipine Besylate | Amlodipine Besylate | 444 | 138 |
| Lisinopril | Lisinopril | 367 | 116 |
| Losartan Potassium | Losartan Potassium | 319 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 80 |
| Gabapentin | Gabapentin | 253 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 250 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 79 |
| Omeprazole | Omeprazole | 247 | 74 |
| Metformin Hcl | Metformin Hcl | 236 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 54 |
| Sertraline Hcl | Sertraline Hcl | 175 | 45 |
| Ezetimibe | Ezetimibe | 155 | 50 |
| Furosemide | Furosemide | 137 | 50 |
| Potassium Chloride | Potassium Chloride | 135 | 43 |
| Montelukast Sodium | Montelukast Sodium | 132 | 38 |
| Ozempic | Semaglutide | 131 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 37 |
| Carvedilol | Carvedilol | 107 | 35 |
| Valsartan | Valsartan | 103 | 34 |
| Alendronate Sodium | Alendronate Sodium | 101 | 25 |
| Simvastatin | Simvastatin | 101 | 26 |
| Eliquis | Apixaban | 93 | 27 |
| Famotidine | Famotidine | 85 | 26 |
| Meloxicam | Meloxicam | 84 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 24 |
| Januvia | Sitagliptin Phosphate | 82 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 28 |
| Tradjenta | Linagliptin | 68 | 24 |
| Atenolol | Atenolol | 66 | 22 |
| Celecoxib | Celecoxib | 66 | 17 |
| Clonidine Hcl | Clonidine Hcl | 66 | 20 |
| Glimepiride | Glimepiride | 64 | 18 |
| Trazodone Hcl | Trazodone Hcl | 64 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 62 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 18 |
| Ibuprofen | Ibuprofen | 56 | 19 |
| Spironolactone | Spironolactone | 55 | 13 |
| Glipizide | Glipizide | 52 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 24 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Azithromycin | Azithromycin | 49 | 47 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 13 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 40 | suppressed |
| Allopurinol | Allopurinol | 38 | 13 |
| Mupirocin | Mupirocin | 38 | 19 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 12 |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Methylprednisolone | Methylprednisolone | 32 | 29 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Unithroid | Levothyroxine Sodium | 30 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 25 |
| Trulicity | Dulaglutide | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Finasteride | Finasteride | 22 | suppressed |
| Klor-Con 10 | Potassium Chloride | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Nystatin | Nystatin | 19 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Sumatriptan | Sumatriptan | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $83.61 · 4 records | ABBVIE INC. | ELIQUIS, NURTEC ODT, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error